HK1208810A1 - C-terminal and central epitope a-beta antibodies c a- - Google Patents

C-terminal and central epitope a-beta antibodies c a-

Info

Publication number
HK1208810A1
HK1208810A1 HK15109545.4A HK15109545A HK1208810A1 HK 1208810 A1 HK1208810 A1 HK 1208810A1 HK 15109545 A HK15109545 A HK 15109545A HK 1208810 A1 HK1208810 A1 HK 1208810A1
Authority
HK
Hong Kong
Prior art keywords
terminal
beta antibodies
central epitope
epitope
central
Prior art date
Application number
HK15109545.4A
Other languages
English (en)
Chinese (zh)
Inventor
Manuel Buttini
Ming Chen
Shyra Gardai
Original Assignee
Janssen Alzheimer Immunotherap
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Alzheimer Immunotherap filed Critical Janssen Alzheimer Immunotherap
Publication of HK1208810A1 publication Critical patent/HK1208810A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK15109545.4A 2012-07-03 2015-09-29 C-terminal and central epitope a-beta antibodies c a- HK1208810A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261667891P 2012-07-03 2012-07-03
PCT/US2013/046399 WO2014007982A2 (en) 2012-07-03 2013-06-18 C-terminal and central epitope a-beta antibodies

Publications (1)

Publication Number Publication Date
HK1208810A1 true HK1208810A1 (en) 2016-03-18

Family

ID=49882576

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109545.4A HK1208810A1 (en) 2012-07-03 2015-09-29 C-terminal and central epitope a-beta antibodies c a-

Country Status (13)

Country Link
US (1) US20150353631A1 (pt)
EP (1) EP2869846A4 (pt)
JP (1) JP2015526409A (pt)
KR (1) KR20150036163A (pt)
CN (1) CN105579061A (pt)
AU (1) AU2013287119A1 (pt)
BR (1) BR112014033066A2 (pt)
CA (1) CA2877516A1 (pt)
HK (1) HK1208810A1 (pt)
IL (1) IL236549A0 (pt)
MX (1) MX2014015744A (pt)
RU (1) RU2014153675A (pt)
WO (1) WO2014007982A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3702373T3 (pl) 2013-09-13 2022-12-05 Beigene Switzerland Gmbh Przeciwciała anty-PD1 i ich zastosowanie jako środki terapeutyczne i diagnostyczne
KR102130600B1 (ko) 2014-07-03 2020-07-08 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
KR102524920B1 (ko) 2014-07-22 2023-04-25 아폴로믹스 인코포레이티드 항-pd-1 항체
EP3177649B1 (en) 2014-08-05 2024-02-28 Apollomics Inc. Anti-pd-l1 antibodies
US20180344881A1 (en) * 2015-11-20 2018-12-06 Navidea Biopharmaceuticals, Inc. Formulations for 2-heteroaryl substituted benzofurans
CN105542005B (zh) * 2016-02-03 2018-11-09 大连理工大学 一种抗人淀粉样β肽的纳米抗体及其应用
EP3481393B1 (en) 2016-07-05 2021-04-14 Beigene, Ltd. Combination of a pd-1 antagonist and a raf inhibitor for treating cancer
CN110087680B (zh) 2016-08-19 2024-03-19 百济神州有限公司 使用包含btk抑制剂的组合产品治疗癌症
WO2018137681A1 (en) 2017-01-25 2018-08-02 Beigene, Ltd. Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
JP2020525411A (ja) 2017-06-26 2020-08-27 ベイジーン リミテッド 肝細胞癌のための免疫療法
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
CN116348487A (zh) 2020-07-23 2023-06-27 欧萨尔普罗席纳有限公司 抗淀粉样β抗体
WO2023111168A1 (en) 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag A novel antibody for detection of amyloid beta 42 (aβ42)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2200366T3 (es) * 1997-08-28 2004-03-01 University Of Washington Composiciones de sacaridos para el tratamiento de la enfermedad de alzheimer y otras amiloidoisis.
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
EP3070100B1 (en) * 2000-02-24 2021-07-07 Washington University St. Louis Humanized antibodies that sequester amyloid beta peptide
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
WO2005018424A2 (en) * 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
JP2008524247A (ja) * 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのアミロイドβ抗体
PE20061201A1 (es) * 2005-01-28 2006-11-03 Wyeth Corp Formulaciones liquidas estabilizadas de polipeptido
EP2808032B1 (en) * 2005-12-12 2018-08-01 AC Immune S.A. A beta 1-42 specific monoclonal antibodies with therapeutic properties
EP2185592B1 (en) * 2007-09-13 2013-01-23 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
WO2011106732A1 (en) * 2010-02-25 2011-09-01 Wyeth Llc Pet monitoring of ab-directed immunotherapy
EP2560681A4 (en) * 2010-04-22 2013-09-25 Janssen Alzheimer Immunotherap USE OF TAU FOR MONITORING IMMUNOTHERAPY

Also Published As

Publication number Publication date
EP2869846A4 (en) 2016-01-13
BR112014033066A2 (pt) 2017-08-01
JP2015526409A (ja) 2015-09-10
EP2869846A2 (en) 2015-05-13
CA2877516A1 (en) 2014-01-03
US20150353631A1 (en) 2015-12-10
WO2014007982A2 (en) 2014-01-09
MX2014015744A (es) 2015-06-05
CN105579061A (zh) 2016-05-11
KR20150036163A (ko) 2015-04-07
IL236549A0 (en) 2015-02-26
RU2014153675A (ru) 2016-08-27
AU2013287119A1 (en) 2015-01-22
WO2014007982A3 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
HK1208810A1 (en) C-terminal and central epitope a-beta antibodies c a-
ZA201407927B (en) Anti-egfr antibodies and uses thereof
HRP20190358T1 (hr) Antitijela protiv asic1 i njihova primjena
EP2830660A4 (en) ANTI-SEMA4D ANTIBODIES AND EPITOPES
PL2831117T3 (pl) Przeciwciała anty-TLR4 i ich zastosowania
HK1219961A1 (zh) 人抗α型干擾素抗體
IL235369A0 (en) Anti-transglutaminase 2 antibodies
SG11201508875TA (en) Mab 2 anti-met antibody
SI3016977T1 (sl) Humana protitelesa proti IL-32
EP2771689A4 (en) PEPTIDES USP2A AND ANTIBODIES
SG2013064282A (en) Mab 2 anti-met antibody
GB201209584D0 (en) Modified antibodies
GB201208372D0 (en) Antibodies and uses thereof